CGEM

Cullinan Therapeutics, Inc.

Price Chart

Latest Quote

$15.03

+0.59 (+4.09%)

Current Price

Previous Close	$14.44
Open	$14.80
Day High	$15.56
Day Low	$14.34
Volume	3,114,453

Fetched: 2026-06-19T21:42:53

Stock Information

Shares Outstanding	61.46M
Total Debt	$2.38M
Cash Equivalents	$351.88M
Net Income	$-221.04M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$923.71M
EPS (TTM)	$-3.37
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$483.25M
Income	$-221.04M
Book/sh	$5.96
Cash/sh	$5.73
Employees	109

Financial Ratios

Quick Ratio	10.09
Current Ratio	10.28
Debt/Eq	0.65

Returns & Margins

ROA	-30.57%
ROE	-48.16%

Ownership

Insider Ownership	0.45%
Institutional Ownership	107.82%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-5.95
P/B	2.52

Analyst Data

Recommendation	strong_buy
Target Price	$31.55

Technical Indicators

SMA20	$14.36
SMA50	$14.43
SMA200	$11.42
RSI	40.81
ATR	1.2061

Shares Float	44.27M
Short Float	18.41%
Short Ratio	7.58
Volatility	0.01
Rel Volume	2.37

Performance History

Week	+15.79%
Month	+6.03%
Quarter	+14.91%
6 Months	+47.06%
YTD	+48.52%
Year	+80.65%
3 Years	+23.30%
5 Years	-52.12%
10 Years	-49.75%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$15.03	3,117,300
2026-06-17	$14.44	1,527,500
2026-06-16	$13.55	1,062,300
2026-06-15	$13.61	1,790,100
2026-06-12	$13.70	1,318,100
2026-06-11	$12.98	1,216,200
2026-06-10	$12.05	2,102,400
2026-06-09	$13.18	1,392,100
2026-06-08	$13.28	1,740,300
2026-06-05	$13.51	753,400
2026-06-04	$14.43	983,900
2026-06-03	$15.21	909,000
2026-06-02	$15.34	1,290,400
2026-06-01	$16.21	988,200
2026-05-29	$16.44	1,877,000
2026-05-28	$15.36	793,000
2026-05-27	$15.52	1,344,200
2026-05-26	$15.46	964,800
2026-05-22	$13.84	471,200
2026-05-21	$13.98	705,600
2026-05-20	$14.33	988,500
2026-05-19	$14.18	1,177,400

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

📰 Latest News

Will Health Benefits Weakness Drag Elevance's Q1 Earnings?

Zacks • 2026-04-16T17:33:00Z

Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data

MarketBeat • 2026-03-14T05:11:23Z

Cullinan Therapeutics: Q4 Earnings Snapshot

Associated Press Finance • 2026-03-10T11:23:38Z

Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference

MarketBeat • 2026-03-08T05:03:05Z

Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near

MarketBeat • 2026-02-20T01:12:50Z

TheStreet Pro Analysts Say, “It’s a Stock Picker’s Market – Here Are 4 to Consider”

TipRanks • 2026-02-19T12:17:31Z

Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum

MarketBeat • 2026-02-13T07:09:26Z

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

Zacks • 2026-01-23T13:55:02Z

Cullinan Therapeutics provides corporate update, anticipated 2026 milestones

TipRanks • 2026-01-09T12:15:35Z

Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely?

Simply Wall St. • 2025-12-17T16:17:26Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$241,648,000	$196,919,000	$190,649,000	$132,137,000
Other Income Expense	$-443,000	$-199,000	$-201,000	$276,842,000
Other Non Operating Income Expenses	$-443,000	$-199,000	$239,000	$57,000
Net Non Operating Interest Income Expense	$22,212,000	$29,660,000	$21,627,000	$6,611,000
Operating Expense	$241,648,000	$196,919,000	$190,649,000	$132,137,000
General And Administrative Expense	$54,246,000	$54,016,000	$42,493,000	$40,189,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-219,879,000	$-167,383,000	$-153,162,000	$111,214,000
Net Interest Income	$22,212,000	$29,660,000	$21,627,000	$6,611,000
Interest Income	$22,212,000	$29,660,000	$21,627,000	$6,611,000
Normalized Income	$-219,879,000	$-167,383,000	$-152,758,740	$-88,597,092
Net Income From Continuing And Discontinued Operation	$-219,879,000	$-167,383,000	$-153,162,000	$111,214,000
Total Operating Income As Reported	$-241,648,000	$-196,919,000	$-191,089,000	$144,648,000
Net Income Common Stockholders	$-219,879,000	$-167,383,000	$-153,162,000	$111,214,000
Net Income	$-219,879,000	$-167,383,000	$-153,162,000	$111,214,000
Net Income Including Noncontrolling Interests	$-219,879,000	$-167,575,000	$-155,101,000	$109,195,000
Net Income Continuous Operations	$-219,879,000	$-167,575,000	$-155,101,000	$109,195,000
Pretax Income	$-219,879,000	$-167,458,000	$-169,223,000	$151,316,000
Interest Income Non Operating	$22,212,000	$29,660,000	$21,627,000	$6,611,000
Operating Income	$-241,648,000	$-196,919,000	$-190,649,000	$-132,137,000
Special Income Charges	-	$0	$-440,000	$276,785,000
Per Share
Diluted EPS	$-3.36	$-2.78	$-3.21	$2.38
Basic EPS	$-3.36	$-2.78	$-3.21	$2.46
Other
Tax Effect Of Unusual Items	$0	$0	$-36,740	$76,973,908
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-241,337,000	$-196,613,000	$-189,899,000	$-408,829,000
Reconciled Depreciation	$311,000	$306,000	$310,000	$93,000
EBITDA (Bullshit earnings)	$-241,337,000	$-196,613,000	$-190,339,000	$-132,044,000
EBIT	$-241,648,000	$-196,919,000	$-190,649,000	$-132,137,000
Diluted Average Shares	$58,999,000	$53,771,000	$41,550,000	$46,640,000
Basic Average Shares	$58,999,000	$53,771,000	$41,550,000	$45,164,000
Diluted NI Availto Com Stockholders	$-219,879,000	$-167,383,000	$-153,162,000	$111,214,000
Minority Interests	$0	$192,000	$1,939,000	$2,019,000
Tax Provision	$0	$117,000	$-14,122,000	$42,121,000
Research And Development	$187,402,000	$142,903,000	$148,156,000	$91,948,000
Selling General And Administration	$54,246,000	$54,016,000	$42,493,000	$40,189,000
Other Gand A	$54,246,000	$54,016,000	$42,493,000	$40,189,000
Total Unusual Items	-	$0	$-440,000	$276,785,000
Total Unusual Items Excluding Goodwill	-	$0	$-440,000	$276,785,000
Impairment Of Capital Assets	-	$0	$440,000	$0
Gain On Sale Of Business	-	-	$0	$276,785,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$408,730,000	$590,328,000	$453,703,000	$535,029,000
Total Assets	$448,374,000	$621,824,000	$484,182,000	$561,117,000
Total Non Current Assets	$61,618,000	$207,156,000	$3,991,000	$86,645,000
Other Non Current Assets	$297,000	$366,000	$459,000	$459,000
Investmentin Financial Assets	$58,270,000	$204,440,000	$0	$80,882,000
Current Assets	$386,756,000	$414,668,000	$480,191,000	$474,472,000
Other Current Assets	$8,860,000	$15,691,000	$13,124,000	$7,180,000
Cash Cash Equivalents And Short Term Investments	$377,896,000	$398,977,000	$467,067,000	$467,292,000
Cash And Cash Equivalents	$88,332,000	$83,005,000	$98,434,000	$156,152,000
Prepaid Assets	-	-	-	-
Cash Equivalents	-	-	-	-
Cash Financial	-	-	-	-
Debt
Total Debt	$2,683,000	$2,151,000	$3,590,000	$5,189,000
Long Term Debt And Capital Lease Obligation	$1,903,000	$849,000	$2,150,000	$3,590,000
Current Debt And Capital Lease Obligation	$780,000	$1,302,000	$1,440,000	$1,599,000
Current Debt	-	-	-	$178,000
Other Current Borrowings	-	-	-	$178,000
Liabilities
Total Liabilities Net Minority Interest	$39,644,000	$31,496,000	$30,287,000	$26,088,000
Total Non Current Liabilities Net Minority Interest	$1,903,000	$849,000	$2,150,000	$3,590,000
Current Liabilities	$37,741,000	$30,647,000	$28,137,000	$22,498,000
Other Current Liabilities	$996,000	$1,437,000	$914,000	$1,955,000
Payables And Accrued Expenses	$26,013,000	$17,973,000	$18,796,000	$14,428,000
Payables	$9,625,000	$7,676,000	$10,362,000	$6,942,000
Other Payable	$8,784,000	$5,994,000	$7,869,000	-
Accounts Payable	$841,000	$1,682,000	$2,493,000	$2,660,000
Total Tax Payable	-	-	$0	$4,282,000
Income Tax Payable	-	-	$0	$4,282,000
Non Current Deferred Liabilities	-	-	-	$0
Equity
Common Stock Equity	$408,730,000	$590,328,000	$453,703,000	$535,029,000
Total Equity Gross Minority Interest	$408,730,000	$590,328,000	$453,895,000	$535,029,000
Stockholders Equity	$408,730,000	$590,328,000	$453,703,000	$535,029,000
Gains Losses Not Affecting Retained Earnings	$1,020,000	$-133,000	$-129,000	$-2,601,000
Other Equity Adjustments	$1,020,000	$-133,000	$-129,000	$-2,601,000
Retained Earnings	$-588,119,000	$-368,240,000	$-200,857,000	$-47,695,000
Other
Ordinary Shares Number	$60,244,136	$58,510,610	$42,900,083	$45,796,449
Share Issued	$60,244,136	$58,510,610	$42,900,083	$45,796,449
Tangible Book Value	$408,730,000	$590,328,000	$453,703,000	$535,029,000
Invested Capital	$408,730,000	$590,328,000	$453,703,000	$535,207,000
Working Capital	$349,015,000	$384,021,000	$452,054,000	$451,974,000
Capital Lease Obligations	$2,683,000	$2,151,000	$3,590,000	$5,011,000
Total Capitalization	$408,730,000	$590,328,000	$453,703,000	$535,029,000
Minority Interest	$0	$0	$192,000	$0
Additional Paid In Capital	$995,823,000	$958,695,000	$654,685,000	$585,320,000
Capital Stock	$6,000	$6,000	$4,000	$5,000
Common Stock	$6,000	$6,000	$4,000	$5,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$1,903,000	$849,000	$2,150,000	$3,590,000
Current Capital Lease Obligation	$780,000	$1,302,000	$1,440,000	$1,421,000
Pensionand Other Post Retirement Benefit Plans Current	$9,952,000	$9,935,000	$6,987,000	$4,516,000
Current Accrued Expenses	$16,388,000	$10,297,000	$8,434,000	$7,486,000
Investments And Advances	$58,270,000	$204,440,000	$0	$80,882,000
Held To Maturity Securities	$58,270,000	$204,440,000	$0	$80,882,000
Net PPE	$3,051,000	$2,350,000	$3,532,000	$5,304,000
Accumulated Depreciation	$-969,000	$-658,000	$-352,000	$-135,000
Gross PPE	$4,020,000	$3,008,000	$3,884,000	$5,439,000
Leases	$576,000	$576,000	$576,000	$628,000
Other Properties	$2,630,000	$1,667,000	$2,543,000	$4,130,000
Machinery Furniture Equipment	$814,000	$765,000	$765,000	$681,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$289,564,000	$315,972,000	$368,633,000	$311,140,000

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-175,799,000	$-145,303,000	$-134,483,000	$-127,797,000
Operating Activities
Operating Cash Flow	$-175,750,000	$-145,303,000	$-134,275,000	$-126,664,000
Cash Flow From Continuing Operating Activities	$-175,750,000	$-145,303,000	$-134,275,000	$-126,664,000
Operating Gains Losses	-	-	-	$-276,753,000
Investing Activities
Capital Expenditure	$-49,000	-	$-208,000	$-1,133,000
Investing Cash Flow	$179,989,000	$-136,314,000	$35,806,000	$248,975,000
Cash Flow From Continuing Investing Activities	$179,989,000	$-136,314,000	$35,806,000	$248,975,000
Financing Activities
Issuance Of Capital Stock	$0	$262,652,000	$38,388,000	$0
Financing Cash Flow	$1,088,000	$266,188,000	$40,751,000	$-25,933,000
Cash Flow From Continuing Financing Activities	$1,088,000	$266,188,000	$40,751,000	$-25,933,000
Net Common Stock Issuance	$0	$262,652,000	$38,388,000	$0
Common Stock Issuance	$0	$262,652,000	$38,388,000	$0
Net Other Financing Charges	-	$-4,448,000	-	$-32,128,000
Other
End Cash Position	$88,332,000	$83,005,000	$98,434,000	$156,152,000
Beginning Cash Position	$83,005,000	$98,434,000	$156,152,000	$59,774,000
Changes In Cash	$5,327,000	$-15,429,000	$-57,718,000	$96,378,000
Proceeds From Stock Option Exercised	$1,088,000	$7,984,000	$538,000	$6,020,000
Net Investment Purchase And Sale	$180,038,000	$-136,314,000	$36,014,000	$-24,983,000
Sale Of Investment	$416,572,000	$584,817,000	$409,397,000	$352,933,000
Purchase Of Investment	$-236,534,000	$-721,131,000	$-373,383,000	$-377,916,000
Net PPE Purchase And Sale	$-49,000	$0	$-208,000	$-1,042,000
Purchase Of PPE	$-49,000	$0	$-208,000	$-1,133,000
Change In Working Capital	$14,084,000	$-389,000	$-339,000	$11,176,000
Change In Payables And Accrued Expense	$7,187,000	$2,083,000	$5,605,000	$12,306,000
Change In Accrued Expense	$8,026,000	$2,895,000	$10,054,000	$8,533,000
Change In Payable	$-839,000	$-812,000	$-4,449,000	$3,773,000
Change In Account Payable	$-839,000	$-812,000	$-167,000	$-509,000
Change In Prepaid Assets	$6,897,000	$-2,472,000	$-5,944,000	$-1,130,000
Stock Based Compensation	$36,040,000	$37,824,000	$30,438,000	$27,957,000
Amortization Of Securities	$-6,306,000	$-15,469,000	$-10,154,000	$1,294,000
Depreciation Amortization Depletion	$311,000	$306,000	$310,000	$93,000
Depreciation And Amortization	$311,000	$306,000	$310,000	$93,000
Net Income From Continuing Operations	$-219,879,000	$-167,575,000	$-155,101,000	$109,195,000
Issuance Of Debt	-	$0	$1,825,000	$2,375,000
Net Issuance Payments Of Debt	-	$0	$1,825,000	$175,000
Net Long Term Debt Issuance	-	$0	$1,825,000	$175,000
Long Term Debt Issuance	-	$0	$1,825,000	$2,375,000
Change In Tax Payable	-	$0	$-4,282,000	$4,282,000
Change In Income Tax Payable	-	$0	$-4,282,000	$4,282,000
Asset Impairment Charge	-	$0	$440,000	$0
Repayment Of Debt	-	-	$0	$-2,200,000
Long Term Debt Payments	-	-	$0	$-2,200,000
Net Business Purchase And Sale	-	-	$0	$275,000,000
Sale Of Business	-	-	$0	$275,000,000
Sale Of PPE	-	-	$0	$91,000
Other Non Cash Items	-	-	$131,000	$374,000
Gain Loss On Sale Of PPE	-	-	$0	$-77,000
Gain Loss On Sale Of Business	-	-	$0	$-276,785,000
Interest Paid Supplemental Data	-	-	-	$32,000
Income Tax Paid Supplemental Data	-	-	-	$37,801,000
Gain Loss On Investment Securities	-	-	-	$109,000
Change In Other Current Assets	-	-	-	-

Fetched: 2026-06-16